Introduce yourself and Lilly?
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
I am a Real World Data Consultant for our International Global Patient Outcomes and Real World Evidence Organization and based in Germany. I belong to a team of Real World Data Consultants, who support researchers from multiple departments around the globe (including Health Outcomes/Economics, Pharmacoepidemiology, Discovery and Early Phase research) to look for and evaluate Real World Data for Lilly Research projects and to support data hosting and analysis at Lilly. My team is collaborating with corporate, regional, and affiliate research departments to optimise selection of RWD.
What is your role in EHDEN and what do you personally hope to get out of this role?
I am the Lilly Principal Investigator for the EHDEN project. I am connecting the Lilly team working in different Work Packages as well as connecting experts from various parts of our organisation with tasks and studies conducted within EHDEN. I am keeping our leadership informed about the EHDEN progress and opportunities for Lilly research. My personal benefit from the role is to connect with experts and peers from our Consortium Partners to experience diverse insights and intense thought exchange around a common goal.
What would you consider success at the end of EHDEN?
Today, scientists in public and private research projects struggle to find the right match of routine care data or routine patient monitoring data to answer their research objectives. Data are siloed, fragmented and often not even findable. Success of EHDEN would be a lasting EHDEN platform which makes the data findable and supports research through a trustworthy data access governance, which meets the needs of the researchers as well as the Data Partners. Furthermore, research methods and analytics need to be geared to data, which are not meant for research in the first place. Here there is another success factor for EHDEN: development and refinement of research methods and algorithms and shared learning across the research community.